The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC, March 23, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for…


Previous articleCOMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
Next articleCybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants